… yearly drug for use as an add-on treatment for asthma in … remain inadequately controlled despite treatment with standard-of-care, … FDA and a decision is expected by December 16. Asthma is … in the airways, worsening asthma symptoms. Reducing this inflammation …

… further guidance from the FDA by the end of … weak results of its experimental drugs for eczema and smoker’ … drugmaker is under pressure to diversify its growth beyond the blockbuster asthma drug … decades. The treatment is also the first developed as part of …

… SWIFT trials showed a 54% reduction in clinically significant exacerbations (asthma attacks … ANCHOR trials were presented at the 2025 American Academy of Allergy, Asthma … work to deliver more ambitious treatment goals, develop the next generation standard …

… medications may cause rebound spikes if discontinued, while conditions such as asthma … to lapses in medication access. The physician founders developed the text-based … platform to ensure patients can access necessary medications …

… inflammation leading to the differential development of airway remodelling.34 This … treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial … adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19 …

… published in Annals of Allergy, Asthma & Immunology reveals a … in rare diseases. The FDA has granted approval to Amgen … or inebilizumab-cdon—for the treatment of adults with generalized myasthenia … by the Phase III MINT trial—allows for a highly …

… inhalers, nebulizers and other treatments that families across the … than white Americans to develop asthma, five times more likely … with the cost of treatment, families are left with … required to cover inhalers, medications, and necessary equipment like …

… . A Phase 2 clinical trial for the treatment of asthma is also ongoing … of Breakthrough Therapeutic Drugs is expected to accelerate its development and review … with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized …

… treatment of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The FDA … and SWIFT-2 trials in asthma, significantly reducing the … Expansion for Rare Obesity Drug Rhythm Pharmaceuticals is … , Cushing’s syndrome develops when the body produces …

… Orphan Drug Designation[6] by the US FDA for the treatment … company focused on the development of therapies based on … DFU), respectively. Further clinical trials are now ongoing: a … ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute …